|
Jun 30
|
Zacks.com featured highlights include Exelixis, Lyft and Kinross Gold
|
|
Jun 27
|
Incyte Stock Gets Relative Strength Rating Lift
|
|
Jun 26
|
Stephens Upgrades Exelixis (EXEL) Stock, Raises PT
|
|
Jun 25
|
Exelixis (NasdaqGS:EXEL) Reports Positive Phase 3 Trial Results For Colorectal Cancer
|
|
Jun 25
|
3 Reasons Growth Investors Will Love Exelixis (EXEL)
|
|
Jun 25
|
The Zacks Analyst Blog Highlights Sprouts Farmers Market, Royal Gold, Thomson Reuters, Woodward and Exelixis
|
|
Jun 25
|
23 Stocks That Score High on What Counts in the 2025 Market
|
|
May 30
|
Top 4 Value Stocks With Impressive PEG Ratios to Buy Now
|
|
May 30
|
2 Top Stocks to Buy With Less Than $100
|
|
May 28
|
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
|
|
May 21
|
Exelixis (NasdaqGS:EXEL) Reports Robust Q1 2025 Earnings and Revenue Growth
|
|
May 19
|
ACADIA Pharmaceuticals Stock Sees RS Rating Jump To 93
|
|
May 19
|
Exelixis (EXEL) is a Great Momentum Stock: Should You Buy?
|
|
May 19
|
Unlocking Exelixis (EXEL) International Revenues: Trends, Surprises, and Prospects
|
|
May 16
|
Exploring High Growth Tech Stocks in the US Market
|
|
Apr 17
|
High Growth Tech Stocks To Watch In The US April 2025
|
|
Apr 16
|
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
|
|
Mar 27
|
FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors
|
|
Mar 27
|
Exelixis’ cabozantinib approval ‘certainly positive,’ says Citi
|
|
Mar 26
|
Exelixis to present positive preclinical data across pipeline portfolio at AACR
|